Seeking to characterize sarcomas in terms of immunebiomarkers, Dancsok et al. performed a systematic evaluationof tumor-infiltrating lymphocytes and immune checkpointbiomarker expression in 1072 sarcoma specimensrepresentative of 22 types of sarcoma, along with 236 benignbone and soft-tissue tumors. The more complex the sarcomatype—such as those with complex genomic features (as wellas prior exposure to radiotherapy)—had higher numbers oftumor-infiltrating lymphocytes compared with translocationassociated sarcomas (usually associated with simple genomicfeatures). Increased lymphocytic infiltrates were associatedwith better overall survival among the sarcomas withcomplex genomic features (those lacking recurrent simpletranslocations). Co-expression of PD-(L)1 with LAG-3 and/orTIM-3 was seen in high enough proportions to perhapswarrant additional clinical trials targeting these markers inconjunction with PD-1 blockade, along with furtherexploration of the significance of these markers beingexpressed together.
展开▼
